2.4. Primary Safety Endpoints
thrombosis, acute myocardial infarction, no-reflow, coronary perforations, contrast-induced nephropathy
THROMBOSIS, MYOCARDIAL INFARCTION (MI), ACUTE MYOCARDIAL INFARCTION, MYOCARDIAL INFARCTION, CARDIAC DEATH, VASCULAR ACCESS SITE COMPLICATION, EVENTS, CONTRAST-INDUCED NEPHROPATHY
The primary safety endpoints of this study were PCI-related major adverse cardiovascular events (MACE), comprising cardiac death, non-fatal myocardial infarction (MI), unplanned revascularization, stent thrombosis, flow limiting coronary dissections, no-reflow phenomenon, coronary perforations, coronary distal embolization, vascular access site complications requiring blood transfusion or surgical intervention, and contrast-induced nephropathy requiring hospitalization. Non-fatal MI was defined by criteria for acute myocardial infarction by the Fourth universal definition of myocardial infarction. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and approved by the Ethics Committee of the Riga Stradins University. The ClinicalTrials.gov identifier is NCT05006183.